3 news items
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
IPHA
15 Apr 24
and license agreement, Sanofi is responsible for the development, manufacturing and commercialization
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
IPHA
21 Mar 24
. In this heavily pre-treated population, post-mogamulizumab, with a median of five prior lines of therapy, the global confirmed objective response rate (ORR
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma
IPHA
6 Mar 24
. "However, many patients fail to achieve a response to or develop disease relapse after treatment. In this context, IPH6501 represents
- Prev
- 1
- Next